These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 25675041)

  • 1. Clinical outcomes and prognostic markers in uterine leiomyosarcoma: a population-based cohort.
    Garcia C; Kubat JS; Fulton RS; Anthony AT; Combs M; Powell CB; Littell RD
    Int J Gynecol Cancer; 2015 May; 25(4):622-8. PubMed ID: 25675041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience.
    Lusby K; Savannah KB; Demicco EG; Zhang Y; Ghadimi MP; Young ED; Colombo C; Lam R; Dogan TE; Hornick JL; Lazar AJ; Hunt KK; Anderson ML; Creighton CJ; Lev D; Pollock RE
    Ann Surg Oncol; 2013 Jul; 20(7):2364-72. PubMed ID: 23334251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Uterine leiomyosarcoma: an updated series.
    Rauh-Hain JA; Oduyebo T; Diver EJ; Guseh SH; George S; Muto MG; del Carmen MG
    Int J Gynecol Cancer; 2013 Jul; 23(6):1036-43. PubMed ID: 23714705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of primary site on outcomes in leiomyosarcoma: a review of clinicopathologic differences between uterine and extrauterine disease.
    Farid M; Ong WS; Tan MH; Foo LS; Lim YK; Chia WK; Soh LT; Poon D; Lee MJ; Ho ZC; Jeevan R; Chin F; Teo M; Quek R
    Am J Clin Oncol; 2013 Aug; 36(4):368-74. PubMed ID: 22772425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma.
    Davidson B; Kjæreng ML; Førsund M; Danielsen HE; Kristensen GB; Abeler VM
    Am J Clin Pathol; 2016 Apr; 145(4):449-58. PubMed ID: 27149024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53, epidermal growth factor, and platelet-derived growth factor in uterine leiomyosarcoma and leiomyomas.
    Anderson SE; Nonaka D; Chuai S; Olshen AB; Chi D; Sabbatini P; Soslow RA
    Int J Gynecol Cancer; 2006; 16(2):849-53. PubMed ID: 16681772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinctive outcome in patients with non-uterine and uterine leiomyosarcoma.
    Lamm W; Natter C; Schur S; Köstler WJ; Reinthaller A; Krainer M; Grimm C; Horvath R; Amann G; Funovics P; Brodowicz T; Polterauer S
    BMC Cancer; 2014 Dec; 14():981. PubMed ID: 25523155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of a prognostic nomogram for overall survival in women with uterine leiomyosarcoma.
    Iasonos A; Keung EZ; Zivanovic O; Mancari R; Peiretti M; Nucci M; George S; Colombo N; Carinelli S; Hensley ML; Raut CP
    Cancer; 2013 May; 119(10):1816-22. PubMed ID: 23456762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma.
    Raut CP; Nucci MR; Wang Q; Manola J; Bertagnolli MM; Demetri GD; Morgan JA; Muto MG; Fletcher CD; George S
    Eur J Cancer; 2009 Nov; 45(16):2818-24. PubMed ID: 19647426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen and progesterone receptors expression in uterine malignant smooth muscle tumors: correlation with clinical outcome.
    Raspollini MR; Amunni G; Villanucci A; Boddi V; Simoni A; Taddei A; Taddei GL
    J Chemother; 2003 Dec; 15(6):596-602. PubMed ID: 14998087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of tumor fragmentation in patients with stage I uterine leiomyosarcoma on patterns of recurrence and oncologic outcome.
    Pedra Nobre S; Hensley ML; So M; Zhou QC; Iasonos A; Leitao MM; Ducie J; Chiang S; Mueller JJ; Abu-Rustum NR; Zivanovic O
    Gynecol Oncol; 2021 Jan; 160(1):99-105. PubMed ID: 33158511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of women with recurrent or persistent uterine leiomyosarcoma.
    Rauh-Hain JA; Hinchcliff EM; Oduyebo T; Worley MJ; Andrade CA; Schorge JO; George S; Muto MG; del Carmen MG
    Int J Gynecol Cancer; 2014 Oct; 24(8):1434-40. PubMed ID: 25248114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Prognostic Value of C-Reactive Protein Serum Levels in Patients with Uterine Leiomyosarcoma.
    Schwameis R; Grimm C; Petru E; Natter C; Staudigl C; Lamm W; Koelbl H; Krainer M; Brodowicz T; Reinthaller A; Polterauer S
    PLoS One; 2015; 10(8):e0133838. PubMed ID: 26248232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjuvant chemotherapy in stage I-II uterine leiomyosarcoma: a multicentric retrospective study of 140 patients.
    Mancari R; Signorelli M; Gadducci A; Carinelli S; De Ponti E; Sesana S; Corso S; Chiappa V; Colombo N; Lissoni AA
    Gynecol Oncol; 2014 Jun; 133(3):531-6. PubMed ID: 24631454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003.
    Ayhan A; Gungorduk K; Khatib G; Fırat Cüylan Z; Boran N; Gökçü M; Çelik H; Özgül N; Akbayir Ö; Şimşek T; Bakay A; Faruk Köse M; Tunç M; Küçükgöz Güleç Ü; Koç S; Kuşçu E; Vardar MA; Akilli H; Taskiran C; Mutlu Meydanlı M
    Curr Probl Cancer; 2021 Oct; 45(5):100712. PubMed ID: 33685725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical status and prognostic factors in Japanese patients with uterine leiomyosarcoma.
    Takehara K; Yamashita N; Watanabe R; Teramoto N; Tsuda H; Motohashi T; Harano K; Nakanishi T; Tokunaga H; Susumu N; Ueda Y; Yokoyama Y; Saito T
    Gynecol Oncol; 2020 Apr; 157(1):115-120. PubMed ID: 31983515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey.
    Durnali A; Tokluoğlu S; Özdemir N; Inanç M; Alkiş N; Zengin N; Sönmez ÖU; Küçüköner M;
    Asian Pac J Cancer Prev; 2012; 13(5):1935-41. PubMed ID: 22901150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Old versus new FIGO staging systems in predicting overall survival in patients with uterine leiomyosarcoma: a study of 86 cases.
    Lim D; Wang WL; Lee CH; Dodge T; Gilks B; Oliva E
    Gynecol Oncol; 2013 Feb; 128(2):322-6. PubMed ID: 23153591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NNMT overexpression is an adverse prognostic factor in uterine leiomyosarcoma.
    Türkmen O; Müftüoğlu KH; Dinçer N; Çelik ZE; Akar Inan S
    Turk J Med Sci; 2024; 54(4):804-810. PubMed ID: 39295619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Observations and Molecular Variables of Primary Vascular Leiomyosarcoma.
    Roland CL; Boland GM; Demicco EG; Lusby K; Ingram D; May CD; Kivlin CM; Watson K; Al Sannaa GA; Wang WL; Ravi V; Pollock RE; Lev D; Cormier JN; Hunt KK; Feig BW; Lazar AJ; Torres KE
    JAMA Surg; 2016 Apr; 151(4):347-54. PubMed ID: 26629783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.